Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Sangamo Therapeutics Inc's Business Segments
Sangamo Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 1 | 100% |
Description of Sangamo Therapeutics Inc
Sangamo Therapeutics Inc is a clinical-stage biotechnology company headquartered in Richmond, California, United States.
The company specializes in developing genetic therapies for diseases caused by genetic defects or deficiencies.
Sangamo Therapeutics Inc aims to cure genetic diseases utilizing gene and cellular therapies.
The company's innovative approach involves editing the genetic code of cells to fix the root cause of genetic disorders.
The company's proprietary technology, called zinc finger nuclease (ZFN), enables precise and targeted cutting and editing of the genome.
Sangamo Therapeutics employs various methods and innovative technologies to ensure the delivery of the edited genetic material to the targeted cells.
Sangamo Therapeutics has a wide range of product candidates under different developmental stages, including gene therapies for hemophilia, lysosomal storage disorders, and sickle cell anemia.
Additionally, the company has a pipeline of CAR-T (Chimeric Antigen Receptor T-cell) candidates to treat different cancer types.
Sangamo Therapeutics has established partnerships with other leading pharmaceutical companies, including Pfizer, Novartis, and Sanofi, to co-develop and commercialize its gene therapy products.
Overall, Sangamo Therapeutics Inc is at the forefront of genetic engineering, and it strives to revolutionize the future of medicine by developing gene therapies to provide long-lasting and durable benefits to patients with genetic diseases.
The company specializes in developing genetic therapies for diseases caused by genetic defects or deficiencies.
Sangamo Therapeutics Inc aims to cure genetic diseases utilizing gene and cellular therapies.
The company's innovative approach involves editing the genetic code of cells to fix the root cause of genetic disorders.
The company's proprietary technology, called zinc finger nuclease (ZFN), enables precise and targeted cutting and editing of the genome.
Sangamo Therapeutics employs various methods and innovative technologies to ensure the delivery of the edited genetic material to the targeted cells.
Sangamo Therapeutics has a wide range of product candidates under different developmental stages, including gene therapies for hemophilia, lysosomal storage disorders, and sickle cell anemia.
Additionally, the company has a pipeline of CAR-T (Chimeric Antigen Receptor T-cell) candidates to treat different cancer types.
Sangamo Therapeutics has established partnerships with other leading pharmaceutical companies, including Pfizer, Novartis, and Sanofi, to co-develop and commercialize its gene therapy products.
Overall, Sangamo Therapeutics Inc is at the forefront of genetic engineering, and it strives to revolutionize the future of medicine by developing gene therapies to provide long-lasting and durable benefits to patients with genetic diseases.
Sangamo Therapeutics Inc. is a pioneering biotechnology company at the forefront of gene therapy, cell therapy, genome editing, and gene regulation. It aims to develop innovative solutions for serious diseases by leveraging its proprietary technologies and expertise in these fields. Below is an extensive exploration of the company’s segments, products, and services.
Segments
1. Therapeutics:
In the therapeutics segment, Sangamo develops and commercializes advanced gene and genome editing therapies aimed at treating a variety of serious diseases. The primary focus is on genetic diseases, metabolic disorders, and neurological conditions, which are often difficult to manage with conventional treatments. The company emphasizes not just treatment but potential cures that target the root genetic causes of these disorders.
2. Industrial:
This segment encompasses the provision of genome editing technologies and gene regulation services to numerous sectors, including biotechnology, pharmaceuticals, and agriculture. Sangamo also produces and sells research reagents that facilitate gene editing research globally. This industrial segment plays a crucial role in advancing the field of genetic research and providing tools that researchers need to explore new therapeutic avenues.
Products
1. Gene Therapy:
Sangamos gene therapy initiatives focus on targeted approaches to various genetic diseases. Notable programs include:
- SB-525: A therapeutic candidate designed for the treatment of hemophilia A, which seeks to provide a long-lasting solution by delivering a functioning copy of the gene responsible for the production of Factor VIII, which is deficient in patients.
- SB-318: Developed for Mucopolysaccharidosis Type I (MPS I), this therapy aims to correct the underlying genetic defect leading to enzyme deficiency.
- SB-913: Targeting MPS II, this program seeks to enhance enzyme delivery to correct the metabolic pathway altered in this condition.
2. Genome Editing:
Sangamo utilizes its cutting-edge genome editing technologies, primarily based on zinc finger nucleases (ZFNs), to create precise modifications in the genome. The most advanced project under this umbrella is:
- SB-913: As mentioned earlier, this program is pivotal in the landscape of gene therapy focusing on the genetic corrections necessary for treating MPS II.
3. Cell Therapy:
This product line focuses on utilizing living cells to repair or replace damaged tissues or organs. One of Sangamos key cell therapy initiatives includes:
- TX200: A promising therapeutic candidate aimed at treating HIV by re-engineering a patients immune cells to enhance their ability to combat the virus.
4. Research Reagents:
Sangamo manufactures and supplies an array of research reagents, critical for laboratory work surrounding gene editing technologies. This includes:
- Zinc Finger Proteins: Custom-designed proteins that enable targeted gene editing.
- Plasmids: Essential for cloning, gene expression, and RNA interference applications.
- Viral Vectors: Tools for delivering genetic material into cells, crucial for effective gene therapy.
Services
1. Gene Regulation:
Sangamo provides proprietary gene regulation technologies, particularly employing zinc finger protein technology, which allows researchers to modulate the expression of specific genes in various cell types. This capability is essential for studying gene function and the pathways involved in diseases.
2. Genome Editing Services:
The company offers extensive genome editing services, catering to both academia and industry. Services include:
- Custom-engineered proteins, enzymes, and viral vectors tailored for specific research needs.
- The development of precision gene editing protocols that facilitate research advancements.
3. Cell Line Engineering:
Sangamo also specializes in creating and optimizing cell lines for drug discovery and therapeutic development. Their cell line engineering services include:
- Targeted gene editing to create cell lines with specific modifications.
- Characterization of cell lines to ensure consistent performance in research applications.
- Development of assays to evaluate the functionality and effectiveness of engineered cell lines.
Overall, Sangamo Therapeutics Inc. stands out for its comprehensive array of products and services designed to tackle serious health conditions through innovative solutions in gene therapy, cell therapy, genome editing, and gene regulation. Through its extensive research and development efforts, the company aims to advance the way genetic diseases are treated and managed, providing hope for patients and contributing to the broader field of biotechnology and medicine.
Segments
1. Therapeutics:
In the therapeutics segment, Sangamo develops and commercializes advanced gene and genome editing therapies aimed at treating a variety of serious diseases. The primary focus is on genetic diseases, metabolic disorders, and neurological conditions, which are often difficult to manage with conventional treatments. The company emphasizes not just treatment but potential cures that target the root genetic causes of these disorders.
2. Industrial:
This segment encompasses the provision of genome editing technologies and gene regulation services to numerous sectors, including biotechnology, pharmaceuticals, and agriculture. Sangamo also produces and sells research reagents that facilitate gene editing research globally. This industrial segment plays a crucial role in advancing the field of genetic research and providing tools that researchers need to explore new therapeutic avenues.
Products
1. Gene Therapy:
Sangamos gene therapy initiatives focus on targeted approaches to various genetic diseases. Notable programs include:
- SB-525: A therapeutic candidate designed for the treatment of hemophilia A, which seeks to provide a long-lasting solution by delivering a functioning copy of the gene responsible for the production of Factor VIII, which is deficient in patients.
- SB-318: Developed for Mucopolysaccharidosis Type I (MPS I), this therapy aims to correct the underlying genetic defect leading to enzyme deficiency.
- SB-913: Targeting MPS II, this program seeks to enhance enzyme delivery to correct the metabolic pathway altered in this condition.
2. Genome Editing:
Sangamo utilizes its cutting-edge genome editing technologies, primarily based on zinc finger nucleases (ZFNs), to create precise modifications in the genome. The most advanced project under this umbrella is:
- SB-913: As mentioned earlier, this program is pivotal in the landscape of gene therapy focusing on the genetic corrections necessary for treating MPS II.
3. Cell Therapy:
This product line focuses on utilizing living cells to repair or replace damaged tissues or organs. One of Sangamos key cell therapy initiatives includes:
- TX200: A promising therapeutic candidate aimed at treating HIV by re-engineering a patients immune cells to enhance their ability to combat the virus.
4. Research Reagents:
Sangamo manufactures and supplies an array of research reagents, critical for laboratory work surrounding gene editing technologies. This includes:
- Zinc Finger Proteins: Custom-designed proteins that enable targeted gene editing.
- Plasmids: Essential for cloning, gene expression, and RNA interference applications.
- Viral Vectors: Tools for delivering genetic material into cells, crucial for effective gene therapy.
Services
1. Gene Regulation:
Sangamo provides proprietary gene regulation technologies, particularly employing zinc finger protein technology, which allows researchers to modulate the expression of specific genes in various cell types. This capability is essential for studying gene function and the pathways involved in diseases.
2. Genome Editing Services:
The company offers extensive genome editing services, catering to both academia and industry. Services include:
- Custom-engineered proteins, enzymes, and viral vectors tailored for specific research needs.
- The development of precision gene editing protocols that facilitate research advancements.
3. Cell Line Engineering:
Sangamo also specializes in creating and optimizing cell lines for drug discovery and therapeutic development. Their cell line engineering services include:
- Targeted gene editing to create cell lines with specific modifications.
- Characterization of cell lines to ensure consistent performance in research applications.
- Development of assays to evaluate the functionality and effectiveness of engineered cell lines.
Overall, Sangamo Therapeutics Inc. stands out for its comprehensive array of products and services designed to tackle serious health conditions through innovative solutions in gene therapy, cell therapy, genome editing, and gene regulation. Through its extensive research and development efforts, the company aims to advance the way genetic diseases are treated and managed, providing hope for patients and contributing to the broader field of biotechnology and medicine.